VANCOUVER, British Columbia - In today's trying markets, partnering might seem even more important to the biotech industry than it has in the past, and M&A appears to be the "exit strategy du jour," as one panelist remarked during a Tuesday morning session at the BioPartnering North America conference here, but don't expect big pharma to swoop in and snatch up every biotech firm in distress. (BioWorld Today) Read More
